The Smucker’s fudge topping has a bold faced lie on its packaging (alleged)

The Non-Financial Ledger

People who buy sugar-free products are usually doing it for a reason. Diabetics watching blood sugar, parents trying to give kids a treat without the crash, folks with sensitive stomachs. The complaint describes a product that used the name of a trusted sweetener to sell to exactly those people while allegedly delivering something with the opposite effects.

The plaintiff says he read the words “Sweetened with Splenda” and understood them to mean what any reasonable shopper would: that Splenda was doing the sweetening. What he actually bought, according to the complaint, was a jar led by maltitol syrup, glycerin, and sorbitol. Sugar alcohols the filing links to bloating, gas, diarrhea, stomach cramps, dehydration, and headaches.

The betrayal here is quiet and specific. Someone managing a health condition trusted a label to tell the truth about what they were putting in their body, and the complaint alleges the label pointed at the one ingredient that was barely there.

Legal Receipts

The following passages come directly from the class action complaint filed in the Eastern District of New York.

“Defendant represents to consumers through its packaging that the Products are ‘Sweetened with Splenda.’ This representation sends a clear message to consumers that Splenda is the primary sweetener in the Products.”

• This establishes the core promise the plaintiff says was made on the front of the jar.
• It frames the claim as material: not decorative marketing, but a message about what the product actually is.

“In the Products, ‘Sucralose’ (Splenda) is the last ingredient listed. The ingredient list also includes Sucralose under the heading ‘Contains 2% Or Less Of.'”

• Because ingredients are listed by weight, being last means Splenda is present in the smallest amount of any ingredient.
• The “2% Or Less” heading is a documented admission on Smucker’s own packaging that contradicts the front-label headline.

“Noting the issues with these other sweeteners, the Products provide a disclaimer that ‘[e]xcess consumption may cause a laxative effect (due to maltitol syrup and sorbitol).'”

• Smucker’s own label names maltitol syrup and sorbitol as the sweeteners behind a laxative warning.
• The complaint uses this to show the company knew these ingredients were the real sweetening agents, not Splenda.

“Defendant has profited enormously from its false and misleading representations. The purpose of this action is to require Defendant to change its labeling claims and to provide consumers with monetary relief for its deceptive and misleading product claims.”

• This states the plaintiff’s theory of the case: the labeling was profitable and misleading.
• It defines the two goals sought: corrected labeling and money returned to buyers.

Public Deception: The Front Label Versus the Ingredient List

The complaint’s central claim is a gap between the front of the jar and the back of the jar. Smucker’s own packaging carries both.

• The front label says “Sweetened with Splenda”; the ingredient list places sucralose dead last, under “Contains 2% Or Less Of.”
• The complaint says Smucker leaned on Splenda’s reputation because “consumers often prefer Splenda to other sugar-free sweeteners due to its health benefits.”
• The actual lead sweeteners named are maltitol syrup, glycerin, and sorbitol, none of which carry Splenda’s calorie-free, low-glycemic profile.
• The same packaging that advertises Splenda also warns that excess consumption “may cause a laxative effect (due to maltitol syrup and sorbitol).”

Anatomy of a Sugar-Free Promise

What is presented as one clean “Sweetened with Splenda” claim is, according to the complaint, a stack of other sweeteners doing the real work.

Legal Minimalism: The Letter but Not the Spirit

The complaint describes a label that may be literally accurate in a narrow sense while defeating the entire purpose of ingredient disclosure rules.

• Federal labeling convention requires ingredients to be listed in descending order by weight, a rule meant to tell shoppers what a product is mostly made of; Smucker complied by listing sucralose last, which technically discloses how little there is.
• The front label’s “Sweetened with Splenda” is arguably true in the sense that some Splenda is present, but the complaint alleges it defeats the disclosure system’s purpose by spotlighting the smallest sweetener.
• The laxative-effect disclaimer satisfies a safety-warning function while simultaneously naming maltitol syrup and sorbitol as the real sweeteners, contradicting the headline claim on the same package.
• The result described is a package that can point to each individual line as “correct” while the overall impression steers a reasonable consumer to the opposite of the truth.

“There is hardly any Splenda in the Products at all.”

Societal Impact Mapping

Public Health

The complaint frames this as a health-targeted product allegedly delivering health-adverse ingredients to the people most likely to rely on the label.

• The product targets buyers who choose Splenda specifically because it is calorie-free, does not spike blood glucose, and is described as safe for diabetics.
• Maltitol syrup, the alleged primary sweetener, is described as not calorie-free and as having “a significant glycemic impact, raising blood sugar levels,” undermining the diabetic-safe expectation.
• Maltitol syrup, glycerin, and sorbitol are each linked in the complaint to digestive distress: bloating, gas, diarrhea, stomach cramps, nausea, and vomiting.
• Glycerin is described as “particularly risky for children in high amounts, potentially causing low blood sugar and intoxication.”
• The product’s own label warns that excess consumption may cause a laxative effect.

Economic Inequality

The complaint alleges consumers paid a premium for a benefit they did not receive.

• The plaintiff paid approximately $3.50 for the topping at a Target in the Bronx, relying on the Splenda claim.
• The complaint states buyers “overpaid for the Products on account of the misrepresentations,” paying for value the product did not carry.
• The plaintiff says he “would not have purchased the Products” or would have paid less had the truth been disclosed.
• The proposed class of harmed New York buyers is estimated in the complaint to “number in the millions,” spreading a small individual overcharge across a very large population.

Who Pays? Following the Cost

The complaint describes a straightforward transfer: consumers absorbed the cost of a claim the product allegedly did not deliver.

• The overcharge originated at the checkout counter, where buyers paid roughly $3.50 per jar on the strength of the Splenda claim.
• The cost was absorbed by individual New York shoppers, especially those with diabetes or digestive sensitivities who selected the product for its advertised profile.
• The complaint alleges Smucker “profited enormously” from the representation, meaning the diffuse per-unit gain accumulated on the corporate side of the ledger.
• Because the class is estimated in the millions, a small overcharge per jar scales into a large aggregate cost shifted from the company onto the public.

The “Cost of a Life” Metric

This is not a fatality case. It is a case about how a trusted health claim translates into a real purchase decision.

The Damage in One Frame

The complaint separates the group harmed, the documented injury, and the scale as alleged in the filing.

This Is the System Working as Intended

The complaint describes a case where the marketing incentive and the disclosure rules pulled in opposite directions, and the marketing won on the front of the package.

• The complaint states Smucker used the Splenda claim “because consumers often prefer Splenda to other sugar-free sweeteners due to its health benefits,” identifying the commercial motive to headline it.
• The ingredient-order rule that should protect shoppers only works if they flip the jar and read a back-panel list, while the persuasive claim sits large on the front.
• The company placed a laxative-effect warning on the same label as the Splenda headline, showing both facts could coexist on packaging without the contradiction being resolved for the buyer.
• Absent this lawsuit, the complaint alleges the labeling would continue, meaning enforcement here depends on a single consumer and his counsel rather than a proactive regulator.

The Settlement Isn’t Justice

No settlement exists yet; this is a freshly filed complaint. But the statutory relief it invokes shows how far individual recovery sits below the alleged harm.

• Under GBL § 349 the complaint seeks “actual damages or $50, whichever is greater,” per consumer, a floor that is a small multiple of a roughly $3.50 purchase.
• Under GBL § 350 it seeks “actual damages or five hundred dollars, whichever is greater” plus treble damages, a stronger figure but one that still turns on proving individual reliance.
• The complaint asks the court to compel a “corrective advertising campaign” and changed labeling, which addresses the future but not the years of alleged sales already made.
• With a class estimated in the millions, per-person statutory minimums can produce a large aggregate number while leaving each individual buyer with a token recovery relative to the trust that was allegedly exploited.

What a Legitimate Fix Looks Like

The core failure this case exposes: a front-of-pack claim was allowed to spotlight the ingredient present in the smallest amount while the real sweeteners hid in the fine print. The following is editorial analysis, not a finding of the source document.

Regulatory Track

• The FDA and FTC should treat a named-sweetener front-label claim (“Sweetened with Splenda”) as requiring that the named sweetener actually be a primary sweetener by weight.
• Require that when a product carries a laxative-effect warning, the sweeteners triggering it cannot be visually subordinated to a trace ingredient in front-panel marketing.
• Mandate that health-halo claims aimed at diabetics disclose glycemic-impact sweeteners like maltitol syrup with equal prominence on the front of the package.

Legislative Track

• Strengthen state consumer-protection statutes like New York GBL §§ 349 and 350 so that “primary ingredient” front-label claims carry a clear, enforceable definition tied to ingredient weight order.
• Raise statutory minimum damages for food-labeling deception so the recovery is not swamped by low unit prices, giving the law real deterrent teeth.
• Enact functional truth-in-front-label standards requiring that any singled-out ingredient claim reflect the product’s actual composition.

Corporate Governance Track

• Smucker should adopt an internal labeling-review rule barring any front-panel ingredient claim for an ingredient listed below the top three by weight.
• Tie marketing and product-labeling sign-off to a compliance officer with authority to veto claims that contradict the back-panel ingredient list.
• Require board-level review of consumer-deception litigation trends so labeling decisions are not made purely inside the marketing function.

What Now?

Direct your attention to The J.M. Smucker Co., organized in Ohio with its principal place of business in Orrville, Ohio, and to the agencies that police food labeling.

• Watchlist: the FTC, which enforces against deceptive advertising, and the FDA, which governs food ingredient labeling standards.
• Watchlist: the New York Attorney General’s office, which enforces the GBL §§ 349 and 350 consumer-protection laws cited in this complaint.
• Read the back-panel ingredient list before you trust the front, and screenshot misleading labels to share with local consumer-protection advocates.
• If you bought this product in New York, follow the docket (Case No. 1:26-cv-04012) and organize with other buyers to preserve receipts and packaging as evidence.
• Support and fund independent consumer watchdogs and mutual-aid food-education groups that teach label literacy in your community.